Hepatocyte-based in vitro model for assessment of drug-induced cholestasis

Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin. Pharmacol. Ther., 89, 806, 10.1038/clpt.2011.58 Alexandre, 2012, Plateable cryopreserved human hepatocytes for the assessment of cytochrome P450 inducibility: experimental condition-related variables affecting their response to inducers, Xenobiotica, 42, 968, 10.3109/00498254.2012.676693 Alrefai, 2007, Bile acid transporters: structure, function, regulation and pathophysiological implications, Pharm. Res., 24, 1803, 10.1007/s11095-007-9289-1 Annaert, 2005, Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes, Drug Metab. Dispos., 33, 388, 10.1124/dmd.104.001669 Ansede, 2010, An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes, Drug Metab. Dispos., 38, 276, 10.1124/dmd.109.028407 Anthërieu, 2013, Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human heparg cells, Hepatology, 57, 1518, 10.1002/hep.26160 Attili, 1986, Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids, Med. Hypotheses, 19, 57, 10.1016/0306-9877(86)90137-4 Balistreri, 2005, Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases single-topic conference, Hepatology, 42, 222, 10.1002/hep.20729 Bohan, 2002, Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions, Semin. Liver Dis., 22, 123, 10.1055/s-2002-30099 Bort, 1999, Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity, J. Pharmacol. Exp. Ther., 288, 65 Chatterjee, 2013, Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: role of glycine conjugates, Toxicol. In vitro Csanaky, 2011, Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: studies in Oatp1b2-null mice, Hepatology, 53, 272, 10.1002/hep.23984 Dawson, 2009, Bile acid transporters, J. Lipid Res., 50, 2340, 10.1194/jlr.R900012-JLR200 Dawson, 2012, In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans, Drug Metab. Dispos., 40, 130, 10.1124/dmd.111.040758 De Bruyn, 2013, Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity, Expert Opin. Drug Metab. Toxicol., 9, 589, 10.1517/17425255.2013.773973 Dhillon, 2009, Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension, Am. J. Cardiovasc. Drugs, 9, 331, 10.2165/11202270-000000000-00000 Elferink, 2007, Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein), Pflugers Arch., 453, 601, 10.1007/s00424-006-0062-9 Epstein, 1998, Molecular pathogenesis of cholestasis, N. Engl. J. Med., 339, 1217, 10.1056/NEJM199810223391707 Fattinger, 2001, The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions, Clin. Pharmacol. Ther., 69, 223, 10.1067/mcp.2001.114667 Fischer, 1996, Hepatic levels of bile acids in end-stage chronic cholestatic liver disease, Clin. Chim. Acta, 251, 173, 10.1016/0009-8981(96)06305-X Fukuda, 2013, HIV protease inhibitors interact with ABCC4/MRP4: a basis for unanticipated enhanced cytotoxicity, Mol. Pharmacol., 84, 361, 10.1124/mol.113.086967 Funk, 2001, Toxicology, 167, 83, 10.1016/S0300-483X(01)00460-7 Gnewuch, 2009, Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease, World J. Gastroenterol., 15, 3134, 10.3748/wjg.15.3134 He, 2004, Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved, Drug Metab. Dispos., 32, 639, 10.1124/dmd.32.6.639 Horikawa, 2003, Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans, Drug Metab. Pharmacokinet., 18, 16, 10.2133/dmpk.18.16 Humbert, 2007, Results of European post-marketing surveillance of bosentan in pulmonary hypertension, Eur. Respir. J., 30, 338, 10.1183/09031936.00138706 Kang, 2008, Bioactivation of flutamide metabolites by human liver microsomes, Drug Metab. Dispos., 36, 1425, 10.1124/dmd.108.020370 Kiang, 2011, Glutathione depletion by valproic acid in sandwich-cultured rat hepatocytes: role of biotransformation and temporal relationship with onset of toxicity, Toxicol. Appl. Pharmacol., 252, 318, 10.1016/j.taap.2011.03.004 Klintmalm, 1981, Cyclosporin A hepatotoxicity in 66 renal allograft recipients, Transplantation, 32, 488, 10.1097/00007890-198112000-00007 Lacerda, 1995, Hepatic levels of cyclosporine and metabolites in patients after liver transplantation, Clin. Transplant., 9, 35 Larrey, 1988, Drug-induced cholestasis, Baillieres Clin. Gastroenterol., 2, 423, 10.1016/0950-3528(88)90010-3 Lebovitz, 2002, Evaluation of liver function in type 2 diabetic patients during clinical trials evidence that rosiglitazone does not cause hepatic dysfunction, Diabetes Care, 25, 815, 10.2337/diacare.25.5.815 Lee, 1953, Tissue distribution of erythromycin in rats, Antibiot. Chemother., 3, 920 Leslie, 2007, Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity, J. Pharmacol. Exp. Ther., 321, 1170, 10.1124/jpet.106.119073 Lewis, 1999, Drug- and chemical-induced cholestasis, Clin. Liver Dis., 3, 433, 10.1016/S1089-3261(05)70079-9 Li, 2002, Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats, Toxicology, 176, 91, 10.1016/S0300-483X(02)00143-9 Manyike, 2000, Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation, Clin. Pharmacol. Ther., 67, 275, 10.1067/mcp.2000.104736 Marion, 2007, Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity, Mol. Pharm., 4, 911, 10.1021/mp0700357 Marra, 2005, Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis, World J. Gastroenterol., 11, 4931 Morgan, 2010, Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development, Toxicol. Sci., 118, 485, 10.1093/toxsci/kfq269 Naschitz, 1995, Ticlopidine-induced prolonged cholestasis, J. Toxicol. Clin. Toxicol., 33, 379, 10.3109/15563659509028930 Navarro, 2006, Drug-related hepatotoxicity, N. Engl. J. Med., 354, 731, 10.1056/NEJMra052270 Obata, 1983, Intrahepatic cholestasis and hyperbilirubinemia in ethynyl estradiol and chlorpromazine-treated rats, Gastroenterol. Jpn., 18, 538, 10.1007/BF02774694 Olson, 2000, Concordance of the toxicity of pharmaceuticals in humans and in animals, Regul. Toxicol. Pharmacol., 32, 56, 10.1006/rtph.2000.1399 Parmentier, 2013, Transcriptomic hepatotoxicity signature of chlorpromazine after short and long-term exposure in primary human sandwich cultures, Drug Metab. Dispos., 41, 1835, 10.1124/dmd.113.052415 Pauli-Magnus, 2006, Hepatobiliary transporters and drug-induced cholestasis, Hepatology, 44, 778, 10.1002/hep.21359 Perez, 2009, Bile-acid-induced cell injury and protection, World J. Gastroenterol., 15, 1677, 10.3748/wjg.15.1677 Rakotondravelo, 2012, Complicated atazanavir-associated cholelithiasis: a report of 14 cases, Clin. Infect. Dis., 55, 1270, 10.1093/cid/cis620 Rao, 2008, The organic solute transporter α–β, Ostα–Ostβ, is essential for intestinal bile acid transport and homeostasis, Proc. Natl. Acad. Sci. U. S. A., 105, 3891, 10.1073/pnas.0712328105 Rodriguez-Garay, 2003, Cholestasis: human disease and experimental animal models, Ann. Hepatol., 2, 150, 10.1016/S1665-2681(19)32126-X Rolo, 2003, Mitochondrially mediated synergistic cell killing by bile acids, Biochim. Biophys. Acta, 1637, 127, 10.1016/S0925-4439(02)00224-7 Scherer, 2009, Rapid quantification of bile acids and their conjugates in serum by liquid chromatography-tandem mass spectrometry, J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 877, 3920, 10.1016/j.jchromb.2009.09.038 Schoonen, 2007, Uniform procedure of 1H NMR analysis of rat urine and toxicometabonomics part II: comparison of NMR profiles for classification of hepatotoxicity, Toxicol. Sci., 98, 286, 10.1093/toxsci/kfm077 Setchell, 1997, Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei, Gastroenterology, 112, 226, 10.1016/S0016-5085(97)70239-7 Stieger, 2000, Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver, Gastroenterology, 118, 422, 10.1016/S0016-5085(00)70224-1 Sulkowski, 2004, Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors, Clin. Infect. Dis., 38, S90, 10.1086/381444 Tchaparian, 2011, Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes, Drug Metab. Dispos., 39, 2387, 10.1124/dmd.111.039545 Ticktin, 1962, Hepatic dysfunction and jaundice in patients receiving triacetyloleandomycin, N. Engl. J. Med., 267, 964, 10.1056/NEJM196211082671905 Wagner, 2009, New molecular insights into the mechanisms of cholestasis, J. Hepatol., 51, 565, 10.1016/j.jhep.2009.05.012 Wolf, 2008, Effect of albumin on the biliary clearance of compounds in sandwich-cultured rat hepatocytes, Drug Metab. Dispos., 36, 2086, 10.1124/dmd.108.020842 Xiang, 2009, Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans, Pharmacogenet. Genomics, 19, 447, 10.1097/FPC.0b013e32832bcf7b Xiang, 2010, High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma, J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 878, 51, 10.1016/j.jchromb.2009.11.019 Xu, 2008, Cellular imaging predictions of clinical drug-induced liver injury, Toxicol. Sci., 105, 97, 10.1093/toxsci/kfn109 Yamazaki, 2013, Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats, Toxicol. Appl. Pharmacol., 268, 79, 10.1016/j.taap.2013.01.018 Yao, 2008, Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model, Br. J. Pharmacol., 154, 1446, 10.1038/bjp.2008.267 Yoshikado, 2013, Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites, Mol. Pharmacol., 83, 552, 10.1124/mol.112.081752 Zahno, 2011, The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells, Biochem. Pharmacol., 81, 432, 10.1016/j.bcp.2010.11.002